Table 1. Patient treatment data and current status.
| Pt ID | Age | Initial/Relapse | Previous Tx | Chemo | # Cycles | Response | Maintenance | Maint.
Length (mo) |
Response | Other Tx | Dead (1)
Alive (0) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 63 | Initial | SCR | 6 | PR | Ofatumumab | 4 | Progression | Bendamustine
Radiation ESHAP GEM-OX Gemzar |
1 | |
| 2 | 79 | Initial | SCR | 4 | PR | Ofatumumab + Sirolimus | 32 | Progression | N/A | 0 | |
| 3 | 66 | Initial | SCR
SCO |
1 SCR
2 SCO |
CR | Ofatumumab | 28 | CR | 0 | ||
| 4 | 55 | Initial | SCR | 6 | PR | Ofatumumab + radiation | 6 | CR | Radiation | 0 | |
| 5 | 79 | Relapse | R-CHOP (PR)
Bortez. (F) Benda + R (F) |
SCR | 2 | Progression | N/A | N/A | N/A | ESHAP
ESHAP Ofatumumab |
0 |
| 6 | 57 | Initial | SCR | 6 | CR | Ritixumab | 8 | CR | 0 | ||
| 7 | 55 | Relapse | Rituxan (F)
Benda + R (PR) Radiation (PR) |
SCR | 6 | CR | Rituximab | 7 | Relapse | Ibrutinib | 0 |
| 8 | 67 | Initial | Velcade (PR) | SCR
SCR+V |
3
2 |
PR
then progression |
Ofatumumab | 4 | Progression | Ofatumumab
Ofa + Bendamustine |
1 |
| 9 | 49 | Initial | SCR
CR |
5
1 |
PR | Rituximab + Radiation | 12 | CR
then relapase |
Bendamustine/Velcade SCT | 1 | |
| 10 | 62 | Initial | SCR | 6 | CR
(Cycle 3) |
Rituximab | 48 | CR | 0 | ||
| 11 | 66 | Initial | SCR | 4 | CR
(Cycle 3) |
N/A | N/A | N/A | Intrathecal chemotherapy
Ara-C + Velcade |
1 | |
| 12 | 59 | Relapse | Hyper-CVAD
R-CHOP Velcade + R (Progression) |
SCR | 2 | Progression
(Cycle 2) |
N/A | N/A | N/A | Bendamustine + Ofatumumab
ESHAP Radiation SCT |
1 |
| 13 | 52 | Relapse | Rituxan
CHOP ESHAP Bortez. |
SCR
SCO |
3
3 |
PR | Ofatumumab | 17 | CR
then relapse |
SCO CR - then relapse
Ofa + RT Ibrutinib - current (PR) |
0 |